← Back to headlines
Argenx Shares Rise on Positive Phase 3 Trial Results for Efgartigimod
Argenx shares have risen significantly following positive results from a Phase 3 study of efgartigimod in an autoimmune myositis trial. The promising data indicates potential for the drug in treating the condition.
17 Aug, 08:13 — 17 Aug, 08:37
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (19/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
morningstarinvesting-com
Right
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
morningstar16d ago
Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod - morningstar.com
Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod morningstar.com
Read full article →investing-com16d ago
Argenx shares jump after positive Phase 3 results in autoimmune myositis trial By Investing.com - Investing.com Philippines
Argenx shares jump after positive Phase 3 results in autoimmune myositis trial By Investing.com Investing.com Philippines
Read full article →Coverage Timeline
First report: investing-com · 17 Aug, 08:13|Full coverage: 2 · 24m|Window: 24m
Left-leaningCenterRight-leaning
Related Stories
Daily News and Photography Digest Aggregates Global Headlines for September 2, 2026
29m ago
Ford Ramps Up Pickup Truck Production Despite August Sales Decline
34m ago
Chevron to Invest $7 Billion to Double Venezuela Oil Output
39m ago
Kennedy Center Begins Removal of Outdoor ‘Blue’ Sculpture Amid Political Pressure
45m ago